Natalie Nicelli

• Merck in its global development and commercialization agreement valued up to $22 billion for three of Daiichi Sankyo’s DXd antibody-drug conjugate candidates for the treatment of multiple solid tumors
• Eli Lilly and Company in its collaboration agreement valued up to $1 billion with Evotec for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases
• Merck in its exclusive license and collaboration agreement with Kelun-Biotech valued up to $9.3 billion to develop seven investigational preclinical antibody-drug conjugates for the treatment of cancer
• Merck in its collaboration agreement valued up to $3.65 billion with Orna Therapeutics to discover, develop, and commercialize circular RNA (oRNA) therapies in multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology, as well as Merck’s $100 million Series B investment in Orna Therapeutics
• Merck in its agreement with Gilead to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV
• Regeneron in its license and collaboration agreement with Nykode Therapeutics for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases
• Regeneron in its up to $1 billion agreement with Alnylam Pharmaceuticals for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system and liver. As part of the transaction, Regeneron made a $400 million investment in Alnylam equity
• Nevakar in its exclusive licensing agreement for the commercialization of NVK-002, a proprietary, investigational, preservative-free eye drop to treat myopia in children ages three to 17, valued up to $135 million with Laboratoires Théa
• Vyera Pharmaceuticals, LLC in its collaboration with CytoDyn Inc. for the commercialization and licensing of leronlimab, a viral-entry inhibitor for the treatment of HIV in which Vyera will pay upfront, regulatory and sales-based milestones totaling $86.5 million, as well as a royalty on net sales of 50 percent, and Vyera will purchase $4 million of CytoDyn common stock

Results may vary depending on your particular facts and legal circumstances.